Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV-2 remains a global threat, despite the rapid deployment but limited coverage of multiple vaccines. Alternative vaccine strategies that have favorable manufacturing timelines, greater ease of distribution, and improved coverage may offer significant public health benefits, especially in resource-limited settings.
Article activity feed
-
-
SciScore for 10.1101/2021.09.13.460191: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: Animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).
IACUC: Animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).Sex as a biological variable Animals, virus stocks, and study design: 21 outbred Indian-origin adult male and female rhesus macaques (Macaca mulatta) ages 6-14 years old were randomly allocated to groups. Randomization Animals, virus stocks, and study design: 21 outbred Indian-origin adult male and … SciScore for 10.1101/2021.09.13.460191: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: Animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).
IACUC: Animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).Sex as a biological variable Animals, virus stocks, and study design: 21 outbred Indian-origin adult male and female rhesus macaques (Macaca mulatta) ages 6-14 years old were randomly allocated to groups. Randomization Animals, virus stocks, and study design: 21 outbred Indian-origin adult male and female rhesus macaques (Macaca mulatta) ages 6-14 years old were randomly allocated to groups. Blinding All immunologic and virologic studies were performed blinded. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources ELISPOT plates were coated with mouse anti-human IFN-γ monoclonal antibody from BD Pharmigen at 5 µg/well and incubated overnight at 4°C. anti-human IFN-γsuggested: NoneExperimental Models: Cell Lines Sentences Resources The WA1/2020 (USA-WA1/2020; BEI Resources; NR-5228) challenge stock was grown in VeroE6 cells and deep sequenced as described previously (33). VeroE6suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Briefly, the packaging plasmid psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and spike protein expressing pcDNA3.1-SARS CoV-2 SΔCT of variants were co-transfected into HEK293T cells by lipofectamine 2000 (ThermoFisher). HEK293Tsuggested: NoneThe mixture was incubated at 37°C for 1 h before adding to HEK293T-hACE2 cells. HEK293T-hACE2suggested: RRID:CVCL_A7UK)Recombinant DNA Sentences Resources Briefly, the packaging plasmid psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and spike protein expressing pcDNA3.1-SARS CoV-2 SΔCT of variants were co-transfected into HEK293T cells by lipofectamine 2000 (ThermoFisher). psPAX2suggested: RRID:Addgene_12260)pLenti-CMVsuggested: NonepcDNA3.1-SARSsuggested: NoneThe gene fragment was subsequently cloned into a pcDNA3.1+ expression plasmid using restriction site cloning (Integrated DNA Technologies). pcDNA3.1+suggested: RRID:Addgene_117272)Software and Algorithms Sentences Resources Statistical analyses: Comparisons of virologic and immunologic data was performed using GraphPad Prism 8.4.2 (GraphPad Software). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
